share_log

BioVie | 10-Q: Q1 2025 Earnings Report

BioVie | 10-Q: Q1 2025 Earnings Report

BioVie | 10-Q：2025财年一季报
美股SEC公告 ·  2024/11/14 05:52

Moomoo AI 已提取核心信息

BioVie reported a net loss of $4.2 million for Q1 FY2025 ended September 30, 2024, significantly lower than the $10.7 million loss in the same period last year. Research and development expenses decreased by $6.9 million to $2.0 million, primarily due to the completion of clinical trials in the prior fiscal year. The company had cash and cash equivalents of $20.0 million as of quarter-end.The company is advancing its neurodegenerative disease program with bezisterim (NE3107), having completed Phase 2 studies for Parkinson's disease and designed a new Phase 2 study as potential first-line therapy. Additionally, BioVie received a $13.1 million Department of Defense grant to evaluate bezisterim for long COVID treatment, with trials expected to commence by early 2025.For its liver disease program BIV201, BioVie is finalizing Phase 3 study protocols for treating ascites due to chronic liver cirrhosis after receiving FDA guidance. The company strengthened its financial position through multiple offerings, raising approximately $15.9 million in gross proceeds in October 2024 through registered direct offerings of common stock and warrants.
BioVie reported a net loss of $4.2 million for Q1 FY2025 ended September 30, 2024, significantly lower than the $10.7 million loss in the same period last year. Research and development expenses decreased by $6.9 million to $2.0 million, primarily due to the completion of clinical trials in the prior fiscal year. The company had cash and cash equivalents of $20.0 million as of quarter-end.The company is advancing its neurodegenerative disease program with bezisterim (NE3107), having completed Phase 2 studies for Parkinson's disease and designed a new Phase 2 study as potential first-line therapy. Additionally, BioVie received a $13.1 million Department of Defense grant to evaluate bezisterim for long COVID treatment, with trials expected to commence by early 2025.For its liver disease program BIV201, BioVie is finalizing Phase 3 study protocols for treating ascites due to chronic liver cirrhosis after receiving FDA guidance. The company strengthened its financial position through multiple offerings, raising approximately $15.9 million in gross proceeds in October 2024 through registered direct offerings of common stock and warrants.
BioVie报告截至2024年9月30日的2025财年第一季度净亏损420万美金，显著低于去年同期的1070万美金亏损。研发费用减少了690万美金，降至200万美金，主要是由于在前一个财年完成了临床试验。公司在季度结束时拥有现金及现金等价物2000万美金。该公司正在推进其神经退行性疾病项目，使用bezisterim(NE3107)，已完成针对帕金森病的第二阶段研究，并设计了一项新的第二阶段研究作为潜在的一线治疗。此外，BioVie获得了1310万美金的国防部补助，用于评估bezisterim对长期COVID的治疗，预计在2025年初开始进行试验。针对其肝病项目BIV201，BioVie正在根据FDA指导最终确定治疗因慢性肝硬化引起的腹水的第三阶段研究方案。公司通过多次融资增强了财务状况，在2024年10月通过注册直接发行普通股和Warrants筹集了约1590万美金的总收入。
BioVie报告截至2024年9月30日的2025财年第一季度净亏损420万美金，显著低于去年同期的1070万美金亏损。研发费用减少了690万美金，降至200万美金，主要是由于在前一个财年完成了临床试验。公司在季度结束时拥有现金及现金等价物2000万美金。该公司正在推进其神经退行性疾病项目，使用bezisterim(NE3107)，已完成针对帕金森病的第二阶段研究，并设计了一项新的第二阶段研究作为潜在的一线治疗。此外，BioVie获得了1310万美金的国防部补助，用于评估bezisterim对长期COVID的治疗，预计在2025年初开始进行试验。针对其肝病项目BIV201，BioVie正在根据FDA指导最终确定治疗因慢性肝硬化引起的腹水的第三阶段研究方案。公司通过多次融资增强了财务状况，在2024年10月通过注册直接发行普通股和Warrants筹集了约1590万美金的总收入。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日